Pune, India | January 05, 2026
India’s pharmaceutical industry is set to benefit from the upcoming generic semaglutide patent expiry. Analysts predict that this milestone will improve patient access to diabetes and obesity therapies. Furthermore, it offers Indian drugmakers a competitive advantage globally.
Patent protections for semaglutide medicines will soon end in India, Canada, Brazil, and emerging markets. Consequently, multiple companies can introduce generic semaglutide products quickly. Experts estimate this market could generate over Rs 50,000 crore in revenue.
Domestic branded formulations may earn between Rs 10 billion and Rs 20 billion in FY27 as generic semaglutide becomes widely available. Simultaneously, international markets like Canada and Brazil could contribute roughly Rs 45 billion, while other emerging markets may add Rs 5–10 billion.
The launch of generic semaglutide will reduce treatment prices by 30–50% initially. Over time, price cuts could reach 70–75%, making GLP-1 therapies more affordable. Consequently, patients in price-sensitive regions will gain access to effective treatments.
Despite growing competition, analysts expect the market to remain concentrated among five to ten major players. Indian companies, including Alkem Laboratories, Dr. Reddy’s, and Sun Pharmaceuticals, have already received approvals. Other firms are preparing for launch, ensuring early market entry.
Zydus Lifesciences is developing a differentiated injectable generic semaglutide, which may provide a competitive edge. This innovation could capture market share even if the diabetes portfolio is smaller than leading manufacturers.
Regulated markets such as Canada and Brazil offer a combined opportunity near USD 2 billion annually. If generics capture 50% market share and implement 50% price reductions, companies may earn around USD 500 million in these regions.
Competition will intensify after generic entry, and pricing pressures may affect short-term margins. Therefore, firms must plan approvals and marketing strategies carefully to maximize revenue and patient reach.
Emerging markets are likely to provide long-term growth, as regulatory hurdles are lower than in developed countries. Companies like Sun Pharma, Dr. Reddy’s, Alkem, Biocon, and OneSource Specialty Pharma are positioned to leverage global distribution networks.
Suppliers of pen devices and delivery systems will also benefit from increased demand for generic semaglutide, as injectable therapies require compatible tools. This change will strengthen the pharmaceutical supply chain.
Price reductions are expected to encourage faster adoption of GLP-1 therapies globally. Consequently, patients who could not previously afford branded semaglutide will access effective treatments.
Branded manufacturers may face market share losses due to aggressive pricing. Similar trends occurred in other therapeutic categories, where generics reduced treatment costs significantly. Healthcare providers are likely to recommend generic semaglutide widely, knowing affordability improves without reducing efficacy.
However, patent expiry alone does not guarantee smooth market entry. Companies must navigate secondary patents, regulatory approvals, and potential legal challenges to fully benefit. For instance, Indian courts allow exports while restricting domestic sales until patent expiry. Firms must plan international launches strategically.
Despite challenges, analysts remain optimistic. The combination of patent expiry, market readiness, and unmet patient demand creates a major opportunity for Indian pharmaceutical companies. The upcoming generic semaglutide launches could transform diabetes and obesity treatment access worldwide.
India’s pharmaceutical sector may grow 0.5–1% in FY27 due to revenue from generic semaglutide and related product innovations. Strategic investments, timely approvals, and competitive pricing will be critical for maximizing global impact.
About the Author
